We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Emergent CEO Anticipates Resuming Bayview Production of J&J Vaccine
Emergent CEO Anticipates Resuming Bayview Production of J&J Vaccine
Emergent BioSolutions CEO Robert Kramer said that the FDA is currently assessing whether to allow the release of more than 100 million Johnson & Johnson (J&J) vaccine doses that were produced at Emergent’s beleaguered Bayview, Md., facility during the company’s highly publicized cross-contamination incident there earlier this year.